Understanding Immune Responses to Bacteria in Cystic Fibrosis

Plain-English translation of NCT04700358 on ClinicalTrials.gov ↗ · Source last updated May 2024 · Translation generated June 2026 · How we translate trials

What is this trial?

Researchers are studying the natural antibodies that your body makes to fight bacteria that commonly infect cystic fibrosis lungs, such as Pseudomonas aeruginosa or Staphylococcus aureus. By examining your blood, they hope to identify antibodies that neutralize the harmful substances bacteria produce. Understanding these natural defenses could lead to designing new treatments that help your immune system fight these dangerous infections more effectively.

Most people with cystic fibrosis develop chronic bacterial lung infections that are hard to treat. This study exists to find the natural antibodies your body already makes against these bacteria and use that knowledge to create new medicines that could control or prevent these life-threatening infections.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have cystic fibrosis affecting your lungs, whether or not you currently have bacterial infections
you have had or currently have a bacterial lung infection
your blood pressure, heart rate, breathing, oxygen levels, and body temperature are within a healthy range
you weigh at least 50 kg (about 110 pounds)

You likely don't qualify if…

you have very low counts of white blood cells, platelets, or hemoglobin (a sign your blood cells are depleted)
you have heart disease or high blood pressure in your lungs
you have recently donated blood, had significant blood loss, or had major surgery in the past 2–3 months
your health has declined recently, including unexplained weight loss, a lung infection flare-up, or a significant drop in lung function
you are unable to give informed consent or have unstable vital signs

What participation looks like

You would visit the study center at the University Hospital of Cologne to have a blood sample taken. The researchers will analyze your blood to identify antibodies that neutralize bacterial virulence factors. You may also have your B cells (immune cells) studied to help design new monoclonal antibodies. The visit is a one-time outpatient procedure; there is no long-term follow-up or medication to take as part of this study.

AI-generated summary from trial data · Jun 17, 2026 · Not medical advice

Trial locations(1 site)

Germany

CF Study Center, University Hospital Cologne, Cologne